• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » David A. Dodd appointed president and CEO of Aeterna Zentaris

David A. Dodd appointed president and CEO of Aeterna Zentaris

April 26, 2013
CenterWatch Staff

Aeterna Zentaris, an oncology and endocrinology drug development company, has appointed David A. Dodd as president and CEO, succeeding Juergen Engel, PhD. Dodd has also been appointed director on the company's board of directors.

"With the appointment of David, we are taking an important first step in transforming Aeterna Zentaris from a company focused on R&D to a company focused on commercializing the promising compounds in our  pipeline," said Juergen Ernst, chairman of the board of directors.

"David's reputation in the industry as a 'transformation specialist' is well deserved, with a record of successful and dramatic transformations of multiple pharmaceutical and biotechnology enterprises."

Dodd's executive management experience in the pharmaceutical and biotechnology industries spans more than 35 years. From December 2007 to June 2009, he served as president, CEO and chairman of BioReliance, a provider of biological safety and related  testing services. From October 2006 to April 2009, he served as non-executive chairman of Stem Cell Sciences, where he oversaw the  development and implementation of a strategic growth plan,  implementation of an experienced executive team and the sale of the  company to Stem Cells in April 2009.

During Dodd's six-year tenure as president, CEO and director of Serologicals, the market value of that company increased  from $85 million in June 2000 to an all-cash sale to Millipore in July 2006 for $1.5 billion. That successful transformation followed his five-year term as president and CEO of  Solvay Pharmaceuticals, and as chairman of its subsidiary Unimed Pharmaceuticals.  Prior to that, he held various senior  management positions at Wyeth-Ayerst Laboratories, Abbott Laboratories and the Mead Johnson Laboratories division at Bristol-Myers Squibb.

Currently, Dodd serves as chair of the board of directors of GeoVax, a biotechnology company developing innovative, patented HIV/AIDS  vaccines; as a director on the board of Aruna Biomedical, a  privately-held life science development company focused on the  development and commercialization of stem cell research products and  services; and, as a director on the board of PNP Therapeutics, a  clinical stage company developing a novel nucleoside-booster treatment  for solid tumor mass cancers.

He also serves as CEO of RiversEdge BioVentures,  which he founded in 2009. RiversEdge is an investment and advisory firm focused on the life sciences and pharmaceutical industry.

Shareholders are advised that, in place of Engel, Dodd will be one of the management nominees for directors at the company's annual meeting of shareholders to be held on May 8, 2013.Enter Content Here

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing